Immune-related hallmark pathway heterogeneity identifies a prognostic risk signature with independent external validation in glioblastoma
Ahmed M Abdelmaguid, Rasha M A Eltanany, Manal F El-Khadragy, Ahmed E Abdel Moneim · 2026
Read Immune-related hallmark pathway heterogeneity identifies a prognostic risk signature with independent external validation in glioblastoma by Ahmed M Abdelmaguid, Rasha M A Eltanany, Manal F El-Khadragy, Ahmed E Abdel Moneim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13578200.txt.
Description
Ahmed Abdelmaguid and co-authors built a tool that predicts survival in glioblastoma from immune pathway activity, in a 2026 study. Glioblastoma is the most aggressive adult brain tumor, and outcomes vary widely in ways single genes explain poorly. Using tumor RNA data from a large American atlas cohort, the team scored each tumor's activity across hallmark pathways and clustered patients by immune pattern.
These scores varied hugely between patients. Inflammatory and mesenchymal programs, including TNF and interleukin-6 signaling, interferon responses, low-oxygen response, and tissue-remodeling programs, tracked with worse disease. Two immune subtypes emerged with distinct pathway patterns. Joining the prognostic pathways into a risk signature split patients into high- and low-risk groups with different survival times. A second Chinese cohort of its own confirmed the signature. The authors propose this pathway-level signal as a usable basis for risk estimates and, later, treatment matching.
Catalog record
| CREATOR | Ahmed M Abdelmaguid, Rasha M A Eltanany, Manal F El-Khadragy, Ahmed E Abdel Moneim |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |